SEC
SlamSEC
SearchBrowseEarnings

REPLIGEN CORP

Nasdaq:RGEN
Biological Products, (No Diagnostic Substances)·WALTHAM, MA
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

Summary Financials

2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN.

Revenue
$83.5M
+31.5% YoY
FY 2017
Adj. EBITDA
$116.3M
139.2% margin
FY 2025
Net Income
$35.6M
42.6% margin
FY 2025
EPS (Diluted)
$0.63
FY 2025
Stock Price
$121.83
-4.7%
2026-03-10
52W Range
$102.97 – $175.77
P/E Ratio
193.4x
Market Cap
$6.9B
Cash
$757.4M
FY 2025
Total Debt
$525.6M
FY 2025
Net Cash
$231.8M
FY 2025
Enterprise Value
$6.6B
Debt / EBITDA
-2.0x
FY 2017
EV / EBITDA
57.0x
Employees
—